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Background: Mirtazapine (MRZ) is a human antidepressant drug metabolized to 8-OH mirtazapine (8-OH) and
dimethylmirtazapine (DMR) metabolites. Recently, this drug has been proposed as a potential analgesic for use in a
multidrug analgesic regime in the context of veterinary medicine. The aim of this study was to assess the
pharmacokinetics of MRZ and its metabolites DMR and 8-OH in rats.
Findings: Eighteen fasted, healthy male rats were randomly divided into 3 groups (n = 6). Animals in these groups
were respectively administered MRZ at 2 and 10 mg/kg orally and 2 mg/kg intravenously. Plasma MRZ and
metabolite concentrations were evaluated by HPLC-FL detection method. After intravenous administration, MRZ
was detected in all subjects, while DMR was only detected in three. 8-OH was not detected. After oral administration,
MRZ was detected in 3 out of 6 rats treated with 2 mg/kg, it was detected in 6 out of 6 animals in the 10 mg/kg group.
DMR was only detectable in the latter group, while 8-OH was not detected in either group. The oral bioavailability was
about 7% in both groups.
Conclusions: The plasma concentration of the MRZ metabolite 8-OH was undetectable, and the oral bioavailability of
the parental drug was very low.
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Mirtazapine (MRZ) is a tetracyclic antidepressant used
mainly in patients affected by depression. Less commonly
it is also used as a hypnotic, antiemetic, and appetite
stimulant, and for the treatment of anxiety, among other
indications [1].
Recently, MRZ use has been extended to veterinary
species [2-7]. To the best of the Authors’ knowledge, there
is minimal information available on the pharmacokinetics
of MRZ in rats [8]. Hence, the aim of this study was to
investigate the pharmacokinetics of MRZ and its two
metabolites, 8-OH and DMR in rats, after single intravenous
(IV) and oral (PO) administrations.* Correspondence: mgiorgi@vet.unipi.it
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The study protocol was approved by the ethics committee
of animal studies at Tehran University of Medical Sciences.
Study one - Twelve Sprague Dawly male rats, aged
8–10 weeks and weighing 250–300 gr, were used. Animals
were randomly assigned to two treatment groups (I and
II). Each subject belonging to group I received a single
oral dose of 2 mg/kg MRZ using the generic drug in the
form of a 30 mg/tablet (Sandoz, Italy). After fasting for
12 h overnight, these rats (n = 6) received the treatment
by gavage, they remained fasted for 6 h after drug admin-
istration. The second group (n = 6) was also treated in the
morning following fasting, they were given the same dose
of MRZ however this was administered via the intravenous
route (achieved by dissolving pure MRZ hydrochloride
powder in saline to give a 2 mg/mL solution).
Blood samples for pharmacokinetic analysis (0.5 mL)
were collected at intervals of 0, 0.25, 0.5, 0.75, 1, 1.5, 2,
3, 4, 6, 8, 10, 12 and 24 h after MRZ administration via
a cannula in the animals’ right jugular vein, and placedLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Main pharmacokinetic parameters of MRZ after
IV (2 mg/kg) and PO (2 and 10 mg/kg) administration of
MRZ






R2 0.998 ± 0.002 0.972 ± 0.026 0.967 ± 0.032
AUC0-∞ (ng h/mL) 1431 ± 659 95 ± 69 1021 ± 240
Cl (mL//h/kg) 1763 ± 1074 315.7 ± 112.3 7522 ± 6695
VD (mL/kg) 1972 ± 1295 258 ± 91 43210 ± 18018
HL alpha (h) 0.23 ± 0.15 0.10 ± 0.02 2.00 ± 3.16
HL beta (h) 1.7 ± 0.9 2.4 ± 0.5 4.8 ± 1.6
Alpha 3.60 ± 1.37 2.53 ± 0.91 4.54 ± 1.26
Beta 0.63 ± 0.43 0.11 ± 0.04 0.15 ± 0.06
HL abs (h) 0.37 ± 0.22 0.09 ± 0.09 0.14 ± 0.04
Tmax (h) / ± / 0.24 ± 0.23 0.29 ± 0.10
Cmax(h) / ± / 76 ± 39 250 ± 67
F% / ± / 6.6 ± 3.1 7.0 ± 4.2
R2 = correlation coefficient; AUC0-∞ = area under the plasma concentration-time
curve extrapolated to infinity; Cl = clearance; VD = volume of distribution; HL
alpha = distribution half-life; HL beta = disposition half-life; Alpha = distribution
constant; Beta = elimination constant; HL abs = absorption half-life; Tmax = time of
peak; Cmax = peak plasma concentration F% = absolute bioavailability.
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samples were centrifuged at 1000 g for 10 min within
30 min of collection, and the harvested plasma was stored
at −80°C until analysis.
Study 2 - Six Sprague Dawly male rats, aged 8–10 months
and weighing 250–300 gr, were used. After fasting for 12 h
overnight, each subject received a single oral dose of
10 mg/kg MRZ via the oral route in the morning, they
remained fasted for 6 h after drug administration. Blood
samples were collected as for study one. The chromato-
graphic analysis was performed as described in a previous
study [5]. The pharmacokinetic calculations were carried
out by WinNonLin v 5.3 (Pharsight Corp,). The parameters
predicted from the data were maximum concentration
(Cmax) of MRZ and DMR in plasma, and the time required
to reach Cmax (Tmax). The area under the concentration
vs. time curve (AUC0-∞) was calculated using the linear
trapezoidal rule. Oral bioavailability (F%) was computed
from the following formula:
F %ð Þ ¼ AUCOS  DoseIVð Þ= AUCIV  DoseOSð Þ  100
The Shapiro-Wilk test was used to assess the normal
distribution of data. The T student test was used to
estimate any significant differences between the pharma-
cokinetics of MRZ and DMR after the two administration
routes.
Findings
Study one – 2 mg/kg IV and PO administrations
MRZ was quantified in plasma from 0.25 to 24 h or 0.25
to 6 h after IV and PO administrations, respectively.
After the IV injection, DMR was quantified in 3 subjects
while in the remaining subjects trace levels only were
detected (>LOD < LOQ). The AUC ratio of MRZ/DMR
was about 26.
DMR was undetectable in the orally administered
animals because the concentrations were consistently
lower than the LOD. Notably, 8-OH was not detected
in any of the plasma samples (regardless of route of
administration) either, this is surprising considering
the very low LOQ (2 ng/ml) for 8-OH and DMR. Al-
though values were normally distributed according to the
Shapiro-Wilk test, wide variations in plasma concentra-
tions were noticed among the rats, especially after PO
administration.
After IV administration, all data sets were analyzed
using the extended least-squares regression analysis and
a two- or a three-compartment open model. This latter
analysis was not possible in five rats out of the six. In
these rats, statistical analysis of the fit of model to
the curves indicated that the data sets were consist-
ent with a two-compartment body model. After PO
administration, only 3 out of six MRZ data sets fittedthe model. This was a result of the variable and low
concentrations of MRZ detected. Hence, the pharma-
cokinetic data representing this treatment should be
used with prudence (Table 1). The oral bioavailability
was low (6.6±3.1).
The DMR data sets obtained after IV dosing of MRZ,
were modeled according to a non compartmental analysis.
However, the DMR concentrations were low and vari-
able and the resulting data should be carefully evaluated
(Table 2).
Figures 1 and 2 depict the mean semi logarithmic
plasma concentration of MRZ and DMR vs time curves
respectively, after IV and PO treatments.Study two – 10 mg/kg PO administration
This second study was designed to better describe the
pharmacokinetic behavior of MRZ and its metabolites
after PO administration. MRZ showed the highest plasma
concentrations, followed by DMR, while 8-OH was found
in trace concentrations only (< LOQ, > LOD), at all sam-
pling times. The AUC ratio MRZ/DMR value (2), was
much higher than for the IV administration. Surprisingly,
in the elimination phase 3–5 h after the drug administra-
tion, 5 out of 6 subjects showed an unpredicted increase
in plasma concentration, for both MRZ and DMR. This
effect (a sort of double peak curve) was significant enough
to be noticed in the semi-logarithmic mean (n = 6) plasma
concentration vs time curves shown in Figure 3. The
complete set of pharmacokinetic parameters is reported in
Table 2 Main pharmacokinetic parameters of DMR after
IV (2 mg/kg) and PO (10 mg/kg) administration of MRZ
Parameters IV (2 mg/kg) (n = 3) PO (10 mg/kg) (n = 6)
R2 0.932 ± 0.044 0.991 ± 0.008
λz (1/h) 0.34 ± 0.30 0.04 ± 0.02
HL λz (h) 3.64 ± 2.55 19.52 ± 7.95
Tmax (h) 0.83 ± 0.44 1.63 ± 1.60
Cmax (ng/mL) 14.68 ± 10.17 74.58 ± 30.37
AUC0-∞ (ng h/mL) 54.50 ± 42.98 506.50 ± 274.12
R2 = correlation coefficient; λz = terminal phase rate constant; HL λz = terminal
half-life; Tmax = time of peak; Cmax = peak plasma concentration AUC0-∞ = area
under the plasma concentration-time curve extrapolated to infinity.
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with this dose rate.
Discussion
Recently, there has been movement to investigate po-
tential applications of MRZ in veterinary medicine. In
the past few years, MRZ has been tested in cats [3,4],
dogs [2] and horses [5]. MRZ caused significant poly-
phagia in cats [4]. It was hypothesized to be potentially
useful for dogs [2] for treatment of anorexia and
anxiety-related diseases [9]; exploitation of its antiemetic
properties (due to antagonism of 5-HT3 receptor) was also
considered. In horses, it was suggested as being an an-
algesic potentially suitable for chronic pain due to its
influence on both the noradrenergic and serotonic spinal
descending pathways [10]. In rats, MRZ showed significant








Figure 1 Observed semilogarithmic mean plasma concentrations vs. t
following IV single dose administration of MRZ at 2 mg/kg in male raPharmacokinetics and metabolism have been reported
as being highly variable among these species [5]. Although
MRZ has been shown to have a good safety profile,
caution should be taken in extrapolating doses from
other animal species or humans. The low oral bioavail-
ability value found in the current study is noteworthy.
To the best of the Authors’ knowledge, this is the first
study to report oral bioavailability of MRZ in rats. The
oral bioavailability value in humans is 50% [11], but no
data is present for any animal species. Since MRZ is
mainly administered orally, and its bioavailability might
vary considerably among animal species, this parameter
should be carefully evaluated in each species. However,
even though oral bioavailability in rats is low, the effective-
ness of the drug (as an analgesic) has been previously dem-
onstrated [6]. This may suggest that the receptors involved
are easily activated, even at low drug concentrations.
This speculation could also be supported by the earlier
observation of its biphasic activity: its effectiveness was
reduced when the dose was increased in rats [6].
Other interesting differences between species have been
found in the plasma concentrations of metabolites. 8-OH,
which is known to be the predominant metabolite in
humans (approximately 40%, [12]) and dogs [2], was not
detectable in the present study, mirroring what is reported
for horses [5]. The metabolism of MRZ in humans is
regulated by phase I biotransformation catalyzed by the en-
zymes CYP1A2 and CYP2D6 (8-hydroxylation), CYP3A4
[9-11] and probably, CYP3A5 (N-demethylation and N-
oxidation) [13]. It is unlikely that the variation in plasma
metabolite concentrations between previous human studies
and the rat samples in the current study are due to species12 18 24
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Figure 2 Observed semilogarithmic mean plasma concentrations vs. time curves of MRZ (―○―) [n = 3] following PO single dose
administration of MRZ at 2 mg/kg in male rats.
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CYP2D isoforms share a high sequence identity (>70%)
[14]. Additionally, recent studies from Matsubara et al.
[15] have identified the new rat CYP3A62 form, and its
expression profile is similar to that of human CYP3A4
and rat CYP3A9. The catalytic activities of these enzymes
are higher in rats than in humans, but this alone can not
account for the large difference in bioavailability. The
most plausible explanation is that phase II enzymes ac-
count for this difference. It is suspected that the 8-OH
metabolite is widely conjugated by glucuronic acid, as sev-







Figure 3 Observed semilogarithmic mean plasma concentrations vs. t
following PO single dose administration of MRZ at 10 mg/kg in malepattern in rats. The rapid elimination of 8-OH as a glucu-
ronide might account for the failure to detect 8-OH in the
rat plasma [16]. Further studies are necessary to clarify
this issue.Conclusion
In conclusion, the present study demonstrates that there
are large species differences in MRZ pharmacokinetics.
Its oral bioavailability is quite low in rats. The in vivo
metabolic pattern appears to be different from that in
other animal species and humans.12 18 24
e (hours)
ime curves of MRZ (―○―) [n = 6] and DMR (―●―) [n = 6]
rats.
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